Xenon Pharmaceuticals
XENE
54 hedge funds and large institutions have $145M invested in Xenon Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
5.72% less ownership
Funds ownership: 68.15% → 62.44% (-5.7%)
10% less funds holding
Funds holding: 60 → 54 (-6)
16% less capital invested
Capital invested by funds: $173M → $145M (-$28.2M)
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
Top Sellers
XENE Hedge Fund Activity: Q3 2019 in Review
54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2019, worth a combined $145M — down 16% from $173M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XENE and 4 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 11 added.
The largest buyer was NEA Management Company, adding an estimated $3.97M. The largest seller was Vivo Capital, exiting entirely with an estimated $13.9M sold.
- 54 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2019, down from 60 in Q2 2019.
- Funds reported $145M of Xenon Pharmaceuticals stock for Q3 2019, down 16% quarter-over-quarter.
- 4 funds opened new Xenon Pharmaceuticals positions in Q3 2019 and 10 closed out, a net change of -6 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2019 was NEA Management Company, an estimated $3.97M added.
- The largest Xenon Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $13.9M sold.
Based on aggregated 13F filings for Q3 2019.